ArticleActa orthopaedica2026
Association of polyethylene type with revision and dislocation risk following primary total hip arthroplasty: a population-based cohort study from the Danish Hip Arthroplasty Register.
Article in Acta orthopaedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHighly cross-linked polyethylene (HXLPE) has been widely adopted to address wear in total hip arthroplasty (THA), yet population-based evidence remains limited. We aimed to evaluate the long-term risk of all-cause revision, dislocation, and cause-specific revision according to polyethylene type in primary THA.
methodsWe conducted a population-based cohort study using data from the Danish Hip Arthroplasty Register and the Danish National Patient Register, including 48,618 patients undergoing primary THA for osteoarthritis from 2000 to 2016. Patients were followed until revision, dislocation, death, year 10, or December 2021. We compared HXLPE with non-HXLPE for patients receiving implants with 28 mm, 32 mm, and 36 mm femoral heads. We estimated standardized risk differences using targeted maximum likelihood estimation comparing polyethylene type stratified by femoral head size and standardized to age, sex, fixation, and Charlson Comorbidity Index.
resultsStandardized risk differences showed favorable results for HXLPE regarding all-cause revision (-3.1%, 95% confidence interval [CI] -4.5 to -1.6), dislocation (-1.9%, CI -3.1 to -0.6), revision due to dislocation (-1.3%, CI -1.9 to -0.7), and revision due to infection (-0.9%, CI -1.3 to -0.4) for 36 mm heads, and for dislocation (-1.4%, CI -2.6 to -0.2) and revision due to aseptic loosening (-0.8%, CI -1.1 to -0.5) for 32 mm heads. There was no difference between HXLPE and non-HXPLE for any outcomes for the 28 mm group.
conclusionAmong 36 mm implants, HXLPE was associated with lower risk of dislocation, all-cause revision, and revision due to infection and dislocation. Among 32 mm implants, HXLPE was associated with lower risk of dislocation and aseptic loosening revision. These findings may suggest potential advantages of HXLPE, though caution is warranted given the observational design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.